drugset / Trial / NCT05097716

Study to Evaluate the Effect of Multiple-Dose Ritlecitinib on the Pharmacokinetics (PK) of Tolbutamide

NCT05097716

Phase 1 Completed 12 enrolled Pfizer
NaSequentialOpen-labelBasic science

Summary

This is a Phase 1, 2-period, multiple-dose, open-label, single fixed sequence study of the effect of ritlecitinib on tolbutamide pharmacokinetics in healthy participants.

Timeline

Start
2021-11-02
Primary completion
2022-01-10
Completion
2022-01-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Ritlecitinib Small molecule 200 mg Oral
Subject Tolbutamide Small molecule 500 mg Oral

Indications

No indication recorded.